Lapatinib is a medicine used to treat certain types of breast cancer, especially those that have spread or are advanced. It works by blocking the growth of cancer cells by interfering with signals that tell cells to grow. It's a targeted therapy for breast cancer.
Every report comes from a Lived member, sent anonymously.
Have you tried Lapatinib for Breast Cancer?
Lapatinib, sold under the brand name Tykerb and also available as a generic, is a prescription pill used to treat HER2-positive breast cancer that is advanced or has spread to other parts of the body (metastatic). HER2 (human epidermal growth factor receptor 2) is a growth-signaling protein. In some breast cancers the cells make far too much of it, which pushes them to grow and divide. Testing a tumor sample shows whether a cancer is HER2-positive, and lapatinib is only used when it is. It is always given together with another cancer medicine, and the partner drug depends on the situation. With capecitabine, a chemotherapy pill, it is used for advanced or metastatic HER2-positive breast cancer that has continued to grow after earlier treatment, including trastuzumab (an antibody medicine that also targets HER2), along with chemotherapy drugs from the anthracycline and taxane families. With letrozole, a hormone-blocking pill, it is used for postmenopausal women whose metastatic cancer is both HER2-positive and hormone receptor-positive, meaning it is also fueled by estrogen or progesterone, when hormone therapy is appropriate. Lapatinib is not a replacement for trastuzumab-based treatment. In two head-to-head trials, regimens built on lapatinib worked less well than comparable regimens built on trastuzumab.
Lapatinib is a kinase inhibitor, a type of targeted cancer drug. HER2 and a related protein, EGFR (epidermal growth factor receptor), sit on the surface of cells and pass growth signals inward. The part of each receptor inside the cell acts as a switch, called a tyrosine kinase, that turns those signals on. Lapatinib attaches to that inner switch on both receptors and blocks it, so the cancer cell receives fewer instructions to keep multiplying. This slows or stops the growth of HER2-driven tumors rather than curing advanced cancer. In laboratory studies, lapatinib still slowed breast cancer cells that had been grown to resist trastuzumab, which fits with its use after trastuzumab has stopped working.
Lapatinib comes as 250 mg tablets taken by mouth once a day. With capecitabine, the usual dose is 5 tablets (1,250 mg) every day, while capecitabine is taken on days 1 to 14 of each 21-day cycle. With letrozole, the usual dose is 6 tablets (1,500 mg) every day without breaks. The care team may lower the dose for side effects, serious liver disease or certain interacting medicines, so the number of tablets on the prescription is the one to follow. Timing around food matters. Take lapatinib on an empty stomach, at least one hour before or one hour after a meal, because a meal can raise the amount the body absorbs several-fold and make levels unpredictable. This is the opposite of capecitabine, which is taken with food or within 30 minutes after eating, so people on both usually need a simple schedule. Take all of the day's tablets together at about the same time each day rather than splitting them across the day, and swallow them whole. If a dose is missed and you don't remember until the next day, or if you vomit after taking it, skip that dose and continue as usual. Never double up the next day to make up for it.
Diarrhea is the most common side effect and the one most likely to interrupt treatment. It usually starts early, often within the first week, and is mild for most people, but it can become severe and lead to dehydration. Report any change in bowel habits to the care team promptly, and start the anti-diarrhea plan they give you (often loperamide, an over-the-counter anti-diarrhea medicine) at the first loose stool. Call right away if diarrhea is severe or comes with fever, or with signs of dehydration such as extreme thirst, a dry mouth, passing much less urine or a racing heartbeat. Other common effects include nausea, vomiting, tiredness, mouth sores, reduced appetite, an acne-like rash, and soreness around the nails. With capecitabine, hand-foot syndrome is also common: the palms and soles become red, sore, tingly or peeling. These are often manageable with skin care, medicine or a dose change, so they are worth raising early. Lapatinib carries an FDA boxed warning for liver damage, which is uncommon but can be severe and has been linked to deaths. It can appear days to several months after starting, which is why blood tests check the liver before and throughout treatment. Contact the care team right away for yellowing of the skin or eyes, dark urine, itching, pain in the upper right side of the abdomen, or pale stools. Less often, lapatinib weakens the heart's pumping, inflames the lungs, or causes a serious skin reaction. Call the care team promptly for new shortness of breath, a dry cough that won't settle, a pounding or irregular heartbeat, swelling in the legs or ankles, or a rash that blisters or peels, especially with mouth sores or fever.
Lapatinib is broken down in the liver by an enzyme called CYP3A4, so medicines that speed up or slow down that enzyme can push lapatinib levels too low to work or high enough to raise side effects. Examples to avoid if possible include certain antifungal medicines (ketoconazole, itraconazole, voriconazole), the antibiotic clarithromycin, some HIV medicines (ritonavir and related drugs), the tuberculosis drug rifampin, the seizure medicines carbamazepine and phenytoin, and the herbal supplement St. John's wort. Grapefruit and grapefruit juice also raise lapatinib levels and should be avoided. If one of these medicines is truly needed, the doctor may adjust the lapatinib dose. Lapatinib can also raise the levels of some other drugs. Digoxin, a heart rhythm medicine, roughly triples in the blood, so its level needs checking. Because lapatinib can lengthen the QT interval (a measure of the heart's electrical recovery between beats that, if too long, can trigger a dangerous rhythm), the team takes extra care with other medicines that do the same, and checks and corrects low potassium or magnesium before treatment. Tell the oncology team and pharmacist about every prescription, over-the-counter product and supplement before starting anything new. Lapatinib can harm a developing baby. A pregnancy test is done before starting, and women who could become pregnant, as well as men with a partner who could become pregnant, should use effective birth control during treatment and for 1 week after the last dose. Breastfeeding should also stop until 1 week after the last dose. People with existing liver disease, heart problems, or a personal or family history of heart rhythm problems should make sure the team knows, since these can change the dose or the monitoring plan.
Before the first dose, the team usually checks liver blood tests and heart pumping, often with an echocardiogram (an ultrasound of the heart) or a similar scan that measures ejection fraction, the share of blood the heart pushes out with each beat. Liver tests are then repeated about every 4 to 6 weeks, and heart checks continue during treatment, since most drops in heart function seen in studies happened in the first 12 weeks. Diarrhea and rash tend to appear in the first weeks, so this is when a clear plan for contacting the team matters most. Whether the cancer is responding is judged over months with scans and checkups rather than by how a person feels day to day. In the main trial with capecitabine, adding lapatinib extended the median time before the cancer grew from about 19 weeks to about 27 weeks, and in the trial with letrozole it extended median progression-free time from about 13 to about 35 weeks in HER2-positive disease. Results vary widely between individuals. Treatment usually continues for as long as it is controlling the cancer and side effects remain manageable. Doses are often paused or lowered rather than stopped altogether, and the decision to continue, switch or stop is made together with the oncology team.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Lapatinib, what you've noticed, or ask the community a question.